Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis

Fig. 1

Unadjusted analysis for risk of MACE by baseline eGFR and UACR regardless of treatment. *p values indicated for comparisons with reference groups (eGFR ≥ 60 mL/min/1.73 m2 and UACR < 30 mg/g). †Participants with eGFR < 30 mL/min/1.73 m2 from SUSTAIN 6 were included for the analysis in the eGFR < 45 mL/min/1.73 m2 as well as UACR < 30, ≥30–≤300, and > 300 mg/g subgroups with the following numbers (%): 139 (19.0); 22 (1.1); 20 (2.3); 68 (16.2). ‡SUSTAIN 6 data only; UACR was not measured in PIONEER 6. %, proportion of participants with ≥ 1 cardiovascular event; CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; MACE, major adverse cardiovascular event; N, total number of participants in pooled population or subgroup with eGFR or UACR values at baseline; n, number of participants with ≥ 1 cardiovascular event; UACR, urine albumin:creatinine ratio

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840